Mika K. Poblete

Mika K. Poblete

Auto-generated profile, based on publicly available information

Mika K. Poblete

University of Virginia 3 Charlottesville, VA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
MMMitchell T. McGinty
Mitchell T. McGinty
APAudrey M. Putelo
Audrey M. Putelo
SKSree H. Kolli
Sree H. Kolli
TFTzu-Yu Feng
Tzu-Yu Feng
MDMadison R. Dietl
Madison R. Dietl
MRMelanie Rutkowski
Melanie Rutkowski
Ovarian cancer accounts for more deaths than any other cancer of the female reproductive system. Patients who have ovarian tumors infiltrated with high frequencies of T cells are associated with a greater survival probability. However, therapies to revitalize tumor-associated T cells, such as PD-L1/PD-1 or CTLA4 blockade, are ineffective for the treatment of ovarian cancer. In this study, we demonstrate that for ovarian cancer, Toll-like receptor 5 (TLR5) signaling, for which the only known ligand is bacterial flagellin, governed failure of PD-L1 and CTLA4 blockade. Mechanistically, chronic TLR5 signaling on CD11c+ cells in vivo and in vitro impaired the differentiation of functional IL-12–producing XCR1+CD103+ conventional type 1 dendritic cells, biasing CD11c+ precursor cells toward myeloid subsets expressing high levels of PD-L1. This culminated in impaired activation of CD8+ T cells, reducing CD8+ T-cell function and ability to persist within the ovarian tumor microenvironment. Expansion of XCR1+CD103+ conventional type 1 dendritic cells in situ using Flt3L-Ig in combination with PD-L1 blockade achieved significant survival benefit in TLR5 knockout mice bearing ovarian tumors, whereas no benefit was observed in the presence of TLR5 signaling. Thus, we have identified a host-intrinsic mechanism leading to the failure of PD-L1 blockade for ovarian cancer, demonstrating that chronic TLR5 signaling on CD11c+ cells is a barrier limiting the efficacy of checkpoint therapy.

17 June 2026
Verified
Other
Open access
MMMitchell T. McGinty
Mitchell T. McGinty
APAudrey M. Putelo
Audrey M. Putelo
SKSree H. Kolli
Sree H. Kolli
TFTzu-Yu Feng
Tzu-Yu Feng
MDMadison R. Dietl
Madison R. Dietl
MRMelanie Rutkowski
Melanie Rutkowski
Ovarian cancer accounts for more deaths than any other cancer of the female reproductive system. Patients who have ovarian tumors infiltrated with high frequencies of T cells are associated with a greater survival probability. However, therapies to revitalize tumor-associated T cells, such as PD-L1/PD-1 or CTLA4 blockade, are ineffective for the treatment of ovarian cancer. In this study, we demonstrate that for ovarian cancer, Toll-like receptor 5 (TLR5) signaling, for which the only known ligand is bacterial flagellin, governed failure of PD-L1 and CTLA4 blockade. Mechanistically, chronic TLR5 signaling on CD11c+ cells in vivo and in vitro impaired the differentiation of functional IL-12–producing XCR1+CD103+ conventional type 1 dendritic cells, biasing CD11c+ precursor cells toward myeloid subsets expressing high levels of PD-L1. This culminated in impaired activation of CD8+ T cells, reducing CD8+ T-cell function and ability to persist within the ovarian tumor microenvironment. Expansion of XCR1+CD103+ conventional type 1 dendritic cells in situ using Flt3L-Ig in combination with PD-L1 blockade achieved significant survival benefit in TLR5 knockout mice bearing ovarian tumors, whereas no benefit was observed in the presence of TLR5 signaling. Thus, we have identified a host-intrinsic mechanism leading to the failure of PD-L1 blockade for ovarian cancer, demonstrating that chronic TLR5 signaling on CD11c+ cells is a barrier limiting the efficacy of checkpoint therapy.

2 June 2026 in Cancer Research
Verified
Journal Article
Closed access
APAudrey M. Putelo
Audrey M. Putelo
SBSimona Bajgai
Simona Bajgai
MPMika K. Poblete
Mika K. Poblete
GGGabrielle Guido
Gabrielle Guido
MLMirna Perusina Lanfranca
Mirna Perusina Lanfranca
MRMelanie Rutkowski
Melanie Rutkowski
Breast cancer is the most commonly diagnosed malignancy and a leading cause of cancer-related mortality. Hormone receptor-positive (HR+) tumors represent the most prevalent metastatic subtype, and early dissemination remains a major clinical challenge. Commensal dysbiosis, defined as an inflammatory gut microbiome with low biodiversity, promotes metastasis by inducing mammary gland inflammation. Here, we investigated systemic mechanisms governing dysbiosis-induced metastasis. Metabolomic profiling revealed elevated primary bile acids (BAs) in the dysbiotic fecal microbiome. Sequestration and supplementation approaches demonstrated that, beyond driving metabolic disease and mammary gland inflammation, primary BAs orchestrated enhanced HR+ tumor dissemination via a prostaglandin E2 (PGE2)-dependent pathway. Analysis of The Cancer Genome Atlas (TCGA) showed that BA, insulin resistance, and PGE2 gene signatures associated with reduced survival in patients with HR+ tumors. In complementary analyses using the Epic Cosmos electronic health record database, bile acid sequestrant use was associated with longer restricted mean survival time among patients with metastatic disease. Together, these findings reveal that commensal dysbiosis-associated loss of microbial BA metabolism elevates primary BAs and promotes HR+ metastatic progression through PGE2 signaling.

17 June 2026
Verified
Other
Open access
MMMitchell T. McGinty
Mitchell T. McGinty
APAudrey M. Putelo
Audrey M. Putelo
SKSree H. Kolli
Sree H. Kolli
TFTzu-Yu Feng
Tzu-Yu Feng
MDMadison R. Dietl
Madison R. Dietl
MRMelanie Rutkowski
Melanie Rutkowski
Figure S2. Dendritic cell subsets examined within the tumor microenvironment and tumordraining lymph nodes in tumor-bearing wild type and TLR5 KO mice.

17 June 2026
Verified
Other
Open access
MMMitchell T. McGinty
Mitchell T. McGinty
APAudrey M. Putelo
Audrey M. Putelo
SKSree H. Kolli
Sree H. Kolli
TFTzu-Yu Feng
Tzu-Yu Feng
MDMadison R. Dietl
Madison R. Dietl
MRMelanie Rutkowski
Melanie Rutkowski
Figure S7. Immune phenotyping of TLR5fl/fl x CD11c Cre mice bearing ovarian tumors

17 June 2026
Verified
Other
Open access
MMMitchell T. McGinty
Mitchell T. McGinty
APAudrey M. Putelo
Audrey M. Putelo
SKSree H. Kolli
Sree H. Kolli
TFTzu-Yu Feng
Tzu-Yu Feng
MDMadison R. Dietl
Madison R. Dietl
MRMelanie Rutkowski
Melanie Rutkowski
Figure S4. Phenotypic assessment of FLT3L cultured bone marrow-derived dendritic cells with acute or chronic exposure to bacterial flagellin